PMS-DICLOFENAC-SR 100 MG
DICLOFENAC SODIUM : 100 MG · DIN 02231505 · PHARMASCIENCE INC
Health Canada status: CANCELLED POST MARKET
What is PMS-DICLOFENAC-SR?
PMS-DICLOFENAC-SR 100 MG contains DICLOFENAC SODIUM : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02231505, held by PHARMASCIENCE INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 14-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-DICLOFENAC-SR used for?
Symptomatic treatment of rheumatoid arthritis and osteoarthritis, including degenerative joint disease of the hip.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is PMS-DICLOFENAC-SR called?
The same molecule, DICLOFENAC, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CLOFENE | Latin | Morocco |
| VOLTARENE | Latin | Morocco |
| DIFAL | Latin | Morocco |
| XENID | Latin | Morocco |
| CATAFLAM | Latin | Morocco |
| DICLOBERL | Latin | Morocco |
| Diclofenac Sandoz | Latin | Australia |
| DICLOFENAC-WGR | Latin | Australia |
| DICLOMAX | Latin | Morocco |
| Fenac EC | Latin | Australia |
| Voltaren | Latin | South Africa |
| Voltaren Emulgel | Latin | South Africa |
| FENAC PROMOPHARM | Latin | Morocco |
| Panamor Gel | Latin | South Africa |
| PHARMAFLAM | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02231505 |
|---|---|
| Brand name | PMS-DICLOFENAC-SR |
| Generic / active ingredient | DICLOFENAC SODIUM : 100 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 100 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AB05 DICLOFENAC |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 14-Feb-2022 |
| Original market date | 1997-11-28 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02231505 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2231505 |
| Brand name | PMS-DICLOFENAC-SR |
| Active ingredient / INN | DICLOFENAC SODIUM : 100 MG |
| ATC code | M01AB05 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M01 |
| AHFS class | 28:08.04.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PHARMASCIENCE INC |
How is it administered?
Use lowest effective dose for shortest duration. Tablets: 50mg (enteric-coated), 75mg/100mg (SR). Suppositories: 50mg/100mg. Not for children <16.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to Storage and Stability section).
How is it supplied?
Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section).
Which pack is which?
| Strength on the label | 100 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Packaging as described in the monograph | Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section). |
| Storage | Not explicitly detailed in provided text (refers to Storage and Stability section). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
CABG surgery peri-operative setting; third trimester of pregnancy; breastfeeding; severe heart failure; hypersensitivity to diclofenac/ASA/NSAIDs; active GI ulcer/bleeding; severe hepatic/renal impairment.
Warnings and precautions
Increased risk of serious cardiovascular thrombotic events (MI, stroke); increased risk of serious GI events (bleeding, ulceration, perforation); potential for hepatotoxicity and renal injury.
Is DICLOFENAC in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PHARMA STULLN INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code M01AB05 DICLOFENAC. 15 of 74 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DICLO | 25 MG | TABLET (ENTERIC-COATED) | APOTEX INC | MARKETED | DIN 00839175 |
| APO-DICLO | 50 MG | TABLET (ENTERIC-COATED) | APOTEX INC | MARKETED | DIN 00839183 |
| APO-DICLO SR | 100 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02091194 |
| APO-DICLO SR | 75 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02162814 |
| CAMBIA | 50 MG | POWDER FOR SOLUTION | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 02381680 |
| PMS-DICLOFENAC | 25 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02302616 |
| PMS-DICLOFENAC | 50 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02302624 |
| PRO-DICLOFENAC | 50 MG | TABLET (DELAYED-RELEASE) | PRO DOC LIMITEE | MARKETED | DIN 00870978 |
| SANDOZ DICLOFENAC RAPIDE | 50 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02261774 |
| SANDOZ-DICLOFENAC | 50 MG | SUPPOSITORY | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02261928 |
Who else supplies DICLOFENAC worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DICLOFENAC appears in 17208 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does DICLOFENAC cost around the world?
DICLOFENAC is listed on 10 national price registers Nexara tracks, across 260 pack listings published on 9 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Morocco | PPV (public price) | 26 | 74 | 05 Sep 2026 |
| United States | acquisition | 6 | 41 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 28 | 40 | 02 Sep 2026 |
| South Africa | single exit price | 25 | 35 | 01 Sep 2026 |
| Australia | ex-manufacturer | 9 | 22 | 08 Sep 2026 |
| Romania | max producer price | 15 | 21 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 13 | 13 | 03 Sep 2026 |
| United Kingdom | hospital | 10 | 10 | 31 Aug 2026 |
| Hungary | producer price (ex-factory) | 2 | 3 | 03 Sep 2026 |
| Belgium | public | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.